Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with - PowerPoint PPT Presentation

Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Investor Presentation Richard T. Schumacher President, CEO, and Founder

FORWARD LOOKING STATEMENTS This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company’s filings with the Securities and Exchange Commission. 02

COMPANY OVERVIEW (OTCQB: PBIO) • Develop, Manufacture, & Sell Pressure Cycling Technology (PCT)- Based Instruments & Consumables Repeated cycles of low to high pressures to control molecular interactions e.g., inactivate enzymes, lyse cells, etc. • Multiple Potential Markets, e.g., Life Sciences, Food Safety & Science, Material Science, etc. • Primary Market Focus: Biopharma (PCT Systems for Biomarker Discovery to Validation to QC to Clinic) ~ 270 PCT Systems Installed, 160+ Customers, 100+ Publications…15 Issued Patents • Exclusive, 2-Year, Worldwide, Co-Marketing Agreement with WW Analytical Instrument Leader SCIEX • Recently Released, Next-generation, Computer-driven, PCT Instrument (Barocycler 2320EXTREME) • Revenue: $2.0M in FY16 (One FT Sales Person with Limited Budget Through Q2 2017) • 1H 2017: Record Total ($1.1M) & Product ($1.0M) Revenue ( Led by 16% Increase in Instrument Sales) • Four Additional Field Sales Managers Hired (vs. One FTE Prior); New Contract with Lead Generator • CE Marking Achieved on Recently Released Barocycler 2320EXTREME (the “2320EXT”) • Secondary Market Focus: Nano-emulsions (Made with PBI’s Ultra - Shear Technology, or “UST”) Two Issued UST Patents (China) for Novel Manufacture of Nano- emulsions…Patent Pending in Rest of the World Potential Applications Include: Food Safety (no preservatives), Cosmetics, Pharmaceuticals, Industrial Lubricants Potential Advantages Include: Improved Adsorption, Rapid Uptake, Better Bioavailability, Aesthetically Pleasing • Company Poised for Rapid Growth & to Reach Profitability 3

COMPANY OVERVIEW (OTCQB: PBIO) Management • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’ l Mgr) - Harvard Medical School • Mr. Joseph L. Damasio, Jr., CPA, VP of Finance and CFO CP Bourg, IQE KC, Kopin, PBI, KPMG Consulting, PWC; Boston College (MBA, MFS) • Dr. Edmund Y. Ting, Senior VP of Engineering Avure Technologies (CTO); Flow Int’l (VP R&D); Grumman Aerospace; MIT (Ph.D.) • Dr. Alexander V. Lazarev, VP of R&D Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.) • Dr. Nathan P. Lawrence, VP of Sales & Marketing, Heads of Manufacturing Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.) Board • Jeffrey Peterson, MS Board Chairman • Kevin Pollack, Esq., MBA Audit Committee Chairman • Vito Mangiardi, MBA Compensation Committee Chairman • Mickey Urdea, Ph.D. SAB Chairman • Richard T. Schumacher CEO, Treasurer, Clerk 4

QUALITY OF ANALYSES IN BIOPHARMA STUDIES (DISCOVERY TO CLINIC) DEPENDS SIGNIFICANTLY ON THE QUALITY OF SAMPLE PREPARATION 5

Three Critical Functions in Scientific Research Studies Sample Input Quality = Sample Result Quality Data Sample Analysis Reduction & Preparation Interpretation  Quality of Analytical Equipment & Data Reduction has Increased Over Recent Years  Quality of Methods for Sample Preparation have not Increased Proportionally (weak link)  Quality of Results is Significantly Affected by the Quality of the Sample Preparation  Scientific Discoveries Start with Sample Preparation 6

VALUE PROPOSITION: BIOPHARMA INDUSTRY • Biological Samples are key starting materials of Biomedical Research…these are the Cells, Tissues, Organs, and Organisms from which are Obtained Novel Biomarkers and other Critical Translational Information • Analysis of Proteins, Lipids, DNA, RNA, and Small Molecules (“biomolecules”) from Biological Samples is the Backbone of the Biopharma Industry (Discovery to Clinic) • Quality of Results Depends Significantly on Quality of Sample Preparation • Biological Sample Preparation is a Multi-Billion Dollar Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs Worldwide • Current Sample Preparation Methods are Highly Inadequate: Bottleneck • PCT is a Proven Sample Prep Platform with ~ 270 PCT Systems Installed (~150 Sites) • 100+ Publications Highlight the Advantages of the PCT Platform in Biopharma Sample Preparation (from Discovery to Characterization to QC to - Potentially - the Clinic) 7

VALUE PROPOSITION: BIOPHARMA INDUSTRY GENOMICS NEXT GEN MASS SPECTROMETRY SAMPLE PREP (DNA/RNA) SEQUENCING (DNA) (PROTEINS) FOR ALL OMICS $7.1B in 2015 b $2.7B in 2017 c $2.7B in 2011 a,d $8.4B in 2016 e 500,000 SCIENTISTS ALL BIOPHARMA ALL PROTEOMICS IN 80,000 BIOLOGICAL $160.44B in $21.87B in RESEARCH LABS WORLDWIDE a 2014 f 2021 f a EMMES Group | b Decisive Bio-Insights | c Markets & Markets | d TechNavio | e bcc Research | f Research and Markets 8

PBI INSTRUMENT PORTFOLIO BAROCYCLER™ HUB440 - HUB880 BAROZYME HT48 XSTREAMPCT™ 2320EXT Up to 45,000 psi. Award- Up to 58,000 & Up to 20,000 psi. Up to 58,000 winning, next-generation, 100,000 psi. High throughput psi. On-line multi-functional sample All-purpose pressure analyses sample preparation instrument generators processors 4 1 2 3 5 6 7 Up to 25,000 psi. Lab-Scale UST Novel Pressure Homogenizers Pump EXPLORER ULTRA-SHEAR RF 1700 9 DISCOVERY PLATFORM TECHNOLOGY (UST)

BAROCYCLER 2320EXT: EXTREME INSTRUMENT FOR BIOLOGICAL SAMPLE PREPARATION (DISCOVERY TO CLINIC) SPECIFICATIONS - cGxP-compliant data logging and audit trails - 16 samples per batch - Full support for MicroPestle platform - Pressure: up to 45,000 psi (3.1 kilobar) - Temperature: 4 ° C to 95 ° C (external chiller) or Ambient to 95 ° C (built-in electrical heater) - Unlimited pressure programming - Real-time graphs of pressure and temperature - Enhanced security and user management - Safe low voltage (24V DC) operation 10

PCT APPLICATIONS IN OMICS SPAN ACROSS ALL BIOPHARMA MARKET SEGMENTS FROM DISCOVERY TO CLINIC DEVELOPMENT DISCOVERY CLINIC PROTEOMICS Genomics, NGS Lipidomics Metabolomics 11

APPLICATIONS OF PBI PRODUCTS SPAN ACROSS ALL BIOPHARMA MARKET SEGMENTS FROM DISCOVERY TO CLINIC DEVELOPMENT DISCOVERY CLINIC 12

PCT PLATFORM IN THE LABS OF KOLS WORLDWIDE Professor J. Van Eyk Prof. Patricia Okubara Professor Cathy Royer Professor Wayne Hubbell Ced edars Sinai USD SDA – WSU SU Re Renssel elaer Po Poly. y. Inst. UCLA Biomarker Discovery Biomarker Discovery Protein Folding Kinetics Protein Structure Heart Disease Microbe Diversity in Soil Rational Drug Design Drug Discovery & Design Professor Bruce Kristal Professor Bruce McCord Prof. Ruedi Aebersold Prof. Phil Robinson Harv Ha rvard Me Medical School Florida Int’l Univ. ET ETH, Zuri rich, Swi Switzer erland Pr ProCan (CMRI), Syd ydney, y, AU AU Metabolomics/Lipidomics Forensics – DNA Testing WW Proteomic Leader Proteomic Mass Spec for Fecal Lipidomic Profiling Improved Rape Kit Testing Tissue Biopsy Analysis by PCT-SWATH Precision Medicine & Therapy 13

CHILDREN’S MEDICAL RESEARCH INSTITUTE (AUSTRALIA) SCIEX Announces Alliance with CMRI on Feb 3, 2016 CMRI Designated Official Collaborator – US Cancer Moonshot – by VP Joe Dr Dr. Phil Robin inson, Co Co-Head of of Biden on July 16, 2016 CMRI, said id: “sample siz ize has has In In th the past lim imited th the use use of of mass spec- • CMRI will test 70,000 tumor samples by based proteomics in in clin inical PCT-SWATH research but but the use of th of PCT will now allo llow researchers to to analyze • CMRI has purchased 4 tis issue samples as as small as as ones SCIEX MSs, 3 PBI provided by pro by ne needle biopsies” . Barocyclers & PCT Dr. Phil Robinson Consumables • First of what could be many centers WW for “industrialized proteomics” 14

SEARCHING FOR PROTEIN BIOMARKERS FROM TUMOR SAMPLES PCT-assisted digestion for tissue proteomic biomarker discovery ProCan, CMRI, Sydney, AU Dr. Philip Robinson Thomas P. Conrads, PhD ProCan (CMRI), Sydney, AU Associate Director of Scientific Technologies Inova Schar Proteomic Mass Spec for Precision Medicine & Therapy Cancer institute 15

CANCER MOONSHOT INITIATIVE PBI’s Barocycler 2320EXTREME to Play Important Role in the Cancer Moonshot Initiative • Announced by President Obama in Jan 2016 PROGRAM AIMS TO ACCELERATE • VP Biden Continues to Play Major Role RESEARCH & SUPPORT OTHER • Approximately $1 Billion will be used to CHANGES THAT WILL IMPROVE THE Support the Program ABILITY TO PREVENT, DETECT, • The US National Cancer Institute (“NCI”) will TREAT, & CURE CANCER Coordinate the Effort • Academia, Industry, Government Laboratories WW will Collaborate 16